• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Direct Flow aims to use heart valve giants’ experience against them

Direct Flow aims to use heart valve giants’ experience against them

February 12, 2013 By Arezu Sarvestani

Direct Flow Medical CEO Bernie Lyons

Being one of the smallest players on the field means you’ve got to differentiate yourself to stand out against the titans of the game, and that’s what Direct Flow Medical CEO Bernie Lyons aims to do.

Direct Flow and its transcatheter aortic valve implantation technology must face down some of the medical device industry’s largest players, including Medtronic (NYSE:MDT), Boston Scientific (NYSE:BSX), Edwards Lifesciences (NYSE:EW) and St. Jude Medical (NYSE:STJ), in order to gain share in the TAVI arena. Lyons told MassDevice.com that he has simple plan – he’s gaining from others’ experiences.

"The beauty of this market is that the giants have done a great job of developing it," Lyons told us. "In fact, we predicated the company on what we learned from the very early users."

Direct Flow was started in 2004 with the intention of responding to a growing concern among physicians using TAVI technology. Early generations of the heart valves, although effective and comparable to surgical valve replacement, were more prone to a type of valve leakage that could cause death, according to some studies. The devices also came with a steep learning curve for physicians, who usually have only 1 chance at implanting the devices.

Direct Flow developed its bovine tissue valve with an inflatable, flexible cuff to address concerns about leakage, or valve regurgitation, as well as to simplify the implantation process. That design helps the device fit different aortic valve anatomies, Lyons said

"We use a metal-free frame for our valve, which, unlike others, allows us to address some of the key clinical issues in the marketplace," he explained. "Because we have the metal-free structure, it will conform to any annulus in terms of its placement, thereby virtually eliminating aortic regurgitation."

“The beauty of this market is that the giants have done a great job of developing it.”

Other TAVI players have also taken steps to reduce the incidence of regurgitation in their devices. Medtech giant Medtronic in October 2012 reported early results from a pivotal CE Mark trial of its Engager TAVI system, touting reduced valve leakage and easier device deployment. Similar reports came from an early feasibility study of Boston Scientific’s Lotus device, with investigators saying it all but eliminated aortic regurgitation and allowed precise positioning on the 1st attempt.

Direct Flow’s TAVI device is also fully repositionable and retrievable, even after full deployment, Lyons said. Physicians can assess the placement of the device and make adjustments as necessary before completing the procedure.

"The most important thing that the 1st physicians that used the early technology told us was that they wanted something repositionable, so that you could optimize its placement," Lyons said. "You don’t want to treat these patients with aortic stenosis and leave them compromised with another disease of aortic regurgitation."

The flexibility of the metal-free structure also allows the valve to come with the lowest-profile, most flexible delivery system, which further eases the process of threading the device through the body and into the heart, he added.

"This technology really does offer something unique to the marketplace. Because of that ability to optimize and assess the outcome before deploying it’s what we consider a true 2nd-generation device," Lyons told us.

Many elements of Direct Flow’s engineering and market strategy came from watching its predecessors, capitalizing where possible on more than 10 years of TAVI experience. Choosing to avoid a metal structure was 1 of the key factors in differentiating its TAVI system from others, but Direct Flow also took cues from their regulatory bids and clinical programs as well.

“Being in this industry for over 25 years, clinical data is the most important thing to the marketplace.”

"We watched them in all their approaches, and certainly working through the regulatory and clinical process has been very helpful to us, by seeing how they’ve done it," Lyons said. "In our Discover trial, which is a CE Mark trial, we used a core lab, just like the FDA requires and has been done in the U.S. for [Edwards Lifesciences’] Partner I and Partner II trials."

Direct Flow used the Discover trial results to help land a recent CE Mark approval for the European market. The company said it plans to use the data for its FDA application as well. Using an independent core lab to assess all the hemodynamic outcomes for its subjects means the study "is to the standards of the U.S. FDA," Lyons said, adding that Direct Flow was the 1st to publish TAVI study data in that manner.

"Being in this industry for over 25 years, clinical data is the most important thing to the marketplace," he said.

The Discover study demonstrated of Direct Flow’s TAVI system met primary its mortality endpoints, with no incidents of major vascular complications and with 95% of patients experiencing mild or less paravalvular regurgitation at 30 days. The company has begun the FDA submission process, is in "constant discussions" with health regulators and hopes to begin an investigational device exemption study in the 2nd half of this year, Lyons told us.

Edwards Lifesciences is the only medical device maker with FDA permission to market a TAVI system in the U.S., having won approval in November 2011, but others are close. Medtronic’s CoreValve was the 1st valve to hit the global market, landing on European shelves in 2007. But the world’s largest medical device company said it doesn’t expect its TAVI device to win FDA approval until 2014. St. Jude Medical expects to begin U.S. IDE trials this year for its Portico entrant.

For its part, Direct Flow hopes to leverage strong clinical results to draw market share away from well-established industry players.

"Aortic regurgitation is the number 1 clinical issue that our physicians are dealing with for these patients," Lyons said. "Because of our unique design and ability to eliminate that problem, we think that clinicians will accept this technology – despite us being a small, privately held company."

Filed Under: Cardiovascular, News Well, Replacement Heart Valves Tagged With: Direct Flow Medical Inc., MassDevice Q&A

In case you missed it

  • iRhythm stays silent on federal grand jury subpoenas
  • Texas power grid struggles a year after cold stopped semiconductor plants
  • The road to a robot: Medtronic’s development process for Hugo RAS system
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
  • Zimmer Biomet appoints new chief accounting officer
  • Cook Medical makes next-gen in vitro fertilization incubator available in U.S., Canada
  • Boston Scientific co-founder Peter Nicholas is dead at 80
  • How Boston Scientific uses clinical feedback to advance innovation
  • How Stryker includes users for product design in the digital age
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
  • Medtronic must sell Intersect ENT subsidiary to satisfy FTC concerns
  • Abbott partners with Women as One to help more underrepresented clinicians lead trials
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring

RSS From Medical Design & Outsourcing

  • iRhythm stays silent on federal grand jury subpoenas
    More than one year after receiving the first of two federal grand jury subpoenas seeking information about its products and communications with the FDA, iRhythm Technologies has said little publicly about the matter. It would have been easy to miss the San Francisco-based cardiac monitor maker’s initial disclosure last summer. iRhythm (Nasdaq:IRTC) was without a… […]
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
    A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented… […]
  • Texas power grid struggles in heat one year after record cold stopped semiconductor plants
    A heat wave in Texas took at least six power plants offline Friday with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semicondcutor shortage that is still throttling medical device production. There’s no… […]
  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]
  • Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly truth’
    A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT). He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.) Medtronic has more than $500 million in… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS